Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Gemcitabine plus albumin-bound paclitaxel useful for treating advanced SQCLC

13 May 2020

The combination of gemcitabine plus albumin-bound paclitaxel (ABP) appears to be well tolerated and effective in the first-line treatment of patients with advanced squamous cell lung cancers (SQCLCs), according to the results of a phase II study.

Thirty-seven patients (median age, 70 years; 70 percent male) with chemotherapy-naïve stage IV SQCLC received weekly intravenous gemcitabine (1,000 mg/m2) plus ABP (100 mg/m2) infusion in a 3-week on, 1-week off schedule during stage I and a 2-week on, 1-week off schedule in stage II of treatment.

Overall, 19 patients responded to treatment, corresponding to best objective response rate (ORR), the primary study endpoint, of 59 percent (95 percent confidence interval [CI], 42–74). ORRs in stages I and II were 54 percent (7/13 responses) and 63 percent (12/19 responses), respectively. The overall disease control rate was 100 percent (18 partial responses, one complete response, 12 stable disease).

Median progression-free survival was 7.5 months (95 percent CI, 6.7–10.5), while median overall survival was 14.2 months (95 percent CI, 12.2–24.5).

There were no unexpected toxicities. Commonly reported adverse events (AEs) were fatigue (30 percent), peripheral oedema (11 percent), and dysgeusia, nail changes, lung infection, rash and peripheral neuropathy (8 percent each). Treatment-related severe AEs occurred in seven patients (19 percent), but none of them died.

The present data suggest that gemcitabine plus ABP is a reasonable alternative in SQCLC patients with contraindications to immune checkpoint inhibitor or platinum therapy, researchers said. Furthermore, the combination represents a promising chemotherapy backbone for future chemo-immune checkpoint inhibitor combinations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.